In an exclusive conversation with Deccan Chronicle, Dr. G Vikram Kumar sheds light on the complexities of hemophilia, its impact on patients’ lives, and the recent breakthroughs in the ...

The U.S. Food and Drug Administration (FDA) approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce ...

Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and ...

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...

The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.

Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...

The FDA approved Pfizer’s Hympavzi, which can be an alternative to intravenous infusions often administered multiple times a ...

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

The approval of Hympavzi Friday was a dose of good news for Pfizer, which is dealing with research setbacks and a challenge ...

In this randomized controlled trial, fidanacogene elaparovovec therapy significantly reduced the mean annualized rate of ...

The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...